Search

Your search keyword '"Harari, Olivier"' showing total 5 results
Start Over Author "Harari, Olivier" Language undetermined
5 results on '"Harari, Olivier"'

1. Additional file 1: of CDP7657, an anti-CD40L antibody lacking an Fc domain, inhibits CD40L-dependent immune responses without thrombotic complications: an in vivo study

Author

Shock, Anthony, Burkly, Linda, Wakefield, Ian, Peters, Christopher, Garber, Ellen, Ferrant, Janine, Taylor, Frederick, Lihe Su, Yen-Ming Hsu, Hutto, David, Amirkhosravi, Ali, Meyer, Todd, Francis, John, Malcolm, Sarah, Robinson, Martyn, Brown, Derek, Shaw, Stevan, Foulkes, Roland, Lawson, Alastair, Harari, Olivier, Bourne, Timothy, Maloney, Alison, and Weir, Neil

Abstract

Inhibition of secondary immune response in Cynomolgus monkeys. CDP7657 at 5 or 20 mg/kg (60 mg/kg was not evaluated in this study) was compared with hu5c8 at 20 mg/kg. Animals were administered a single dose of antibody or i.v saline. and challenged with tetanus toxoid (TT) on day 1; they then received a second dose of antibody and TT on day 30. Data are expressed as the mean anti-TT IgG titerâ Âąâ standard deviation; approximately 50 % inhibition was observed at 20 mg/kg CDP7657, although this was not statistically significant. ***P

Published
2015
Full Text
View/download PDF

2. Additional file 2: of CDP7657, an anti-CD40L antibody lacking an Fc domain, inhibits CD40L-dependent immune responses without thrombotic complications: an in vivo study

Author

Shock, Anthony, Burkly, Linda, Wakefield, Ian, Peters, Christopher, Garber, Ellen, Ferrant, Janine, Taylor, Frederick, Lihe Su, Yen-Ming Hsu, Hutto, David, Amirkhosravi, Ali, Meyer, Todd, Francis, John, Malcolm, Sarah, Robinson, Martyn, Brown, Derek, Shaw, Stevan, Foulkes, Roland, Lawson, Alastair, Harari, Olivier, Bourne, Timothy, Maloney, Alison, and Weir, Neil

Abstract

Hu5c8, aglycosyl hu5c8 and CDP7657 are all inactive in the absence of sCD40L, as was sCD40L alone. In vitro platelet aggregation assay of human washed platelets. A Hu5c8 (blue), CDP7657 (black) and aglycosyl hu5c8 (red) did not cause platelet aggregation when introduced to platelets without recombinant human soluble CD40L (rhCD40L). B rhCD40L alone (10 Îźg/ml) was also inactive. (PDF 180 kb)

Published
2015
Full Text
View/download PDF

3. Additional file 3: of CDP7657, an anti-CD40L antibody lacking an Fc domain, inhibits CD40L-dependent immune responses without thrombotic complications: an in vivo study

Author

Shock, Anthony, Burkly, Linda, Wakefield, Ian, Peters, Christopher, Garber, Ellen, Ferrant, Janine, Taylor, Frederick, Lihe Su, Yen-Ming Hsu, Hutto, David, Amirkhosravi, Ali, Meyer, Todd, Francis, John, Malcolm, Sarah, Robinson, Martyn, Brown, Derek, Shaw, Stevan, Foulkes, Roland, Lawson, Alastair, Harari, Olivier, Bourne, Timothy, Maloney, Alison, and Weir, Neil

Abstract

CDP7657 immune complex ( IC ) and aglycosyl hu5c8 IC do not induce platelet aggregation in rhesus monkey platelets both in the absence of presence of sub-aggregatory amounts of the platelet agonist (ADP). In vitro aggregation assay of rhesus monkey washed platelets. A CDP7657 IC did not aggregate rhesus monkey washed platelets in the absence (blue and red), or presence (black and green) of ADP. B Similarly, aglycosyl hu5c8 IC did not aggregate rhesus monkey washed platelets in the absence (blue and red), or presence (black and green) of ADP. (PDF 171 kb)

Published
2015
Full Text
View/download PDF

4. Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial

Author

Brunner, Hermine I., Ruperto, Nicolino, Zuber, Zbigniew, Keane, Caroline, Harari, Olivier, Kenwright, Andrew, Peng, Lu, Cuttica, Ruben, Keltsev, Vladimir, Xavier, Ricardo M., Calvo, Inmaculada, Nikishina, Irina, Rubio-Pérez, Nadina, Alexeeva, Ekaterina, Chasnyk, Vyacheslav, Horneff, Gerd, Opoka-Winiarska, Violetta, Quartier, Pierre, Silva, Clovis A., Silverman, Earl, Spindler, Alberto, Baildam, Eileen, Gámir, M. Luz, Martin, Alan, Rietschel, Christoph, Siri, Daniel, Smolewska, Elzbieta, Lovell, Daniel, Martini, Alberto, De Benedetti, Fabrizio, Sherrard, T., Johnson, A., Merritt, A., Long, W., Angioloni, Simona, Carenini, Laura, Pallotti, Chiara, Mosci, Eugenia, Garrone, Marco, Gregorini, Irene, Scala, Silvia, Villa, Luca, Silvestri, Giuseppe, Espada, Graciela, Allen, Roger, Chaitow, Jeffrey, Joos, Rik, Wouters, Carine, Knupp, Sheila, Sztajnbok, Flavio, Cabral, David, Houghton, Kristin, Roth, Johannes, Schmeling, Heinrike, Job-Deslandre, Chantal, Jorgensen, Christian, Konepaut, Isabelle, Minden, Kirsten, Weller, Frank, Gerloni, Valeria, Zulian, Francesco, Burgos-Vargas, Ruben, Salazar, Carolina Duarte, Vallejo, Eunice Solis, Calvo, Armando, Chavez, José, Zavaler, Manuel Ferrandiz, Gruenpeter, Anna, Kobusinska, Katarzyna, Sarychev, Alexey, Zholobova, Elena, Ramanan, Athimalaipet, Woo, Patricia, Gedalia, Abraham, Goodman, Steven, Kimura, Yukiko, Onel, Karen, Schikler, Kenneth, and Wouters, Carine

Subjects
Genetics and Molecular Biology (all), Male, DMARDs (biologic), Juvenile Idiopathic Arthritis, Treatment, Adolescent, Adrenal Cortex Hormones, Antibodies, Monoclonal, Humanized, Antirheumatic Agents, Arthritis, Juvenile, Bronchitis, Cellulitis, Child, Child, Preschool, Disease Progression, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Maintenance Chemotherapy, Methotrexate, Pneumonia, Receptors, Interleukin-6, Remission Induction, Treatment Outcome, Rheumatology, Immunology and Allergy, Immunology, Biochemistry, Genetics and Molecular Biology (all), Arthritis, Juvenile, Biochemistry, chemistry.chemical_compound, Monoclonal, Receptors, Medicine, skin and connective tissue diseases, Humanized, Artrite, Connective tissue disease, Rheumatoid arthritis, Combination, medicine.drug, musculoskeletal diseases, medicine.medical_specialty, General Biochemistry, Genetics and Molecular Biology, Antibodies, Tocilizumab, Drug Therapy, Internal medicine, Preschool, Imunossupressores, business.industry, Interleukin-6, Clinical and Epidemiological Research, medicine.disease, Surgery, Método duplo-cego, chemistry, business
Abstract

ObjectiveTo evaluate the interleukin-6 receptor inhibitor tocilizumab for the treatment of patients with polyarticular-course juvenile idiopathic arthritis (pcJIA).MethodsThis three-part, randomised, placebo-controlled, double-blind withdrawal study (NCT00988221) included patients who had active pcJIA for ≥6 months and inadequate responses to methotrexate. During part 1, patients received open-label tocilizumab every 4 weeks (8 or 10 mg/kg for body weight (BW) ResultsIn part 1, 188 patients received tocilizumab (ConclusionsTocilizumab treatment results in significant improvement, maintained over time, of pcJIA signs and symptoms and has a safety profile consistent with that for adults with rheumatoid arthritis.Trial registration number:NCT00988221.

Published
2014

5. EFFICACY AND SAFETY OF TOCILIZUMAB IN POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS: CHERISH RESULTS AT WEEK 40

Author

Baildam, Eileen, Ruperto, Nicolino, Brunner, Hermine, Zuber, Zbigniew, Keane, Caroline, Harari, Olivier, Kenwright, Andrew, Cuttica, Ruben J., Keltsev, Vladimir, Xavier, Ricardo, Penades, Inmaculada C., Nikishina, Irina, Rubio-Perez, Nadina, Alekseeva, Ekaterina, Chasnyk, Vyacheslav, Chavez, Jose, Horneff, Gerd, Opoka-Winiarska, Violetta, Quartier, Pierre, Silva, Clovis A., Silverman, Earl D., Spindler, Alberto, Lovell, Daniel J., Martini, Alberto, and fabrizio De Benedetti

Catalog

Books, media, physical & digital resources
See catalog results